TABLE 5.
Antibody responses in Syrian golden hamsters inoculated i.p. as weanlings with SV40 parental and recombinant virusesa
| Type of regulatory region and virus | Presence of tumors | No. of hamsters tested | Anti-T-agb
|
Neutralizing antibodyb
|
||
|---|---|---|---|---|---|---|
| No. of positive hamsters (%) | Median titerc (range) | No. of positive hamsters (%) | Median titerc (range) | |||
| Simple | ||||||
| Baylor(1E) | Yes | 10 | 10 (100) | 100 (10-5,000) | 10 (100) | 8,000 (1,000-10,000) |
| No | 2 | 1 (50) | 10 (10) | 2 (100) | 3,200 (200-6,000) | |
| SVCPC | Yes | 18 | 16 (89) | 100 (5-5,000) | 18 (100) | 9,000 (100-10,000) |
| No | 15 | 7 (47) | 100 (10-1,000) | 8 (53) | 1,000 (1,000) | |
| 777 | Yes | 5 | 5 (100) | 100 (10-1,000) | 5 (100) | 2,000 (100-5,000) |
| No | 14 | 3 (21) | 10 (5-100) | 5 (36) | 100 (100-1,000) | |
| 776(1E) | Yes | 4 | 4 (100) | 550 (100-5,000) | 3 (75) | 2,000 (1,000-10,000) |
| No | 11 | 5 (45) | 100 (100) | 7 (64) | 1,000 (100-2,000) | |
| CPC-Baylor | Yes | 7 | 7 (100) | 1,000 (5-1,000) | 7 (100) | 5,000 (1,000-65,000) |
| No | 12 | 9 (75) | 100 (5-100) | 9 (75) | 1,000 (100-2,000) | |
| CPC-PML | Yes | 11 | 10 (91) | 1,000 (10-5,000) | 10 (91) | 2,000 (100-6,000) |
| No | 8 | 4 (50) | 100 (10-100) | 6 (75) | 1,500 (100-6,000) | |
| CPC-776 | Yes | 6 | 3 (50) | 100 (10-5,000) | 5 (83) | 25,000 (1,000-200,000) |
| No | 11 | 4 (36) | 100 (5-1,000) | 4 (36) | 1,000 (100-2,000) | |
| CPC-VA | Yes | 3 | 2 (67) | 2,550 (10-5,000) | 1 (33) | 10,000 (10,000) |
| No | 13 | 2 (15) | 55 (10-100) | 5 (38) | 100 (100-1,000) | |
| Complex | ||||||
| Baylor(2E) | Yes | 1 | 1 (100) | 100 (100) | 1 (100) | 2,000 (2,000) |
| No | 16 | 11 (69) | 5 (2-100) | 8 (50) | 1,000 (100-2,000) | |
| 776(2E) | Yes | 3 | 3 (100) | 1,000 (1,000) | 3 (100) | 1,000 (1,000-70,000) |
| No | 27 | 22 (81) | 100 (5-5,000) | 16 (59) | 1,000 (100-70,000) | |
| VA45-54 | Yes | 3 | 3 (100) | 2,000 (2,000-5,000) | 3 (100) | 6,000 (6,000-10,000) |
| No | 10 | 7 (70) | 10 (5-1,000) | 2 (20) | 550 (10-1,000) | |
| SVPML | Yes | 0 | ||||
| No | 16 | 8 (50) | 100 (5-1,000) | 3 (100)d | 1,000 (100-2,000) | |
| 776-Baylor | Yes | 5 | 5 (100) | 1,000 (10-5,000) | 5 (100) | 2,000 (1,000-6,000) |
| No | 9 | 9 (100) | 100 (10-1,000) | 9 (100) | 1,000 (200-6,000) | |
| 776-CPC | Yes | 1 | 1 (100) | 1,000 (1,000) | 1 (100) | 6,000 (6,000) |
| No | 14 | 12 (86) | 10 (5-100) | 12 (86) | 1,000 (100-2,000) | |
| 776-VA | Yes | 4 | 4 (100) | 100 (100-5,000) | 4 (100) | 1,000 (100-1,000) |
| No | 27 | 15 (56) | 100 (5-100) | 6 (32)d | 1,000 (1,000) | |
| 776-PML | Yes | 1 | 1 (100) | 100 (100) | 1 (100) | 1,000 (1,000) |
| No | 17 | 15 (88) | 10 (5-1,000) | 16 (94) | 550 (100-6,000) | |
| None | ||||||
| Controls | No | 7 | 0 (0) | 0 (0) | ||
a
Sera were collected when tumor-bearing animals were sacrificed or when the experiments were terminated at 12 months after inoculation.
b
Indirect immunofluorescence was performed to detect antibodies against SV40 T-ag, and a specific plaque reduction assay was used to measure neutralizing antibodies against SV40.
c
Titers are expressed as the reciprocal of the highest serum dilution that tested positive. Median titers given are for positive sera only.
d
Neutralizing antibodies were measured in only 3 and 19 tumor-free animals from the SVPML and 776-VA groups, respectively.